Safety and efficacy of cathodal transcranial direct current stimulation in patients with Lennox Gastaut Syndrome: An open-label, prospective, single-center, single-blinded, pilot study

被引:2
|
作者
San-Juan, Daniel [1 ]
Ruiz, Axel Galindo [1 ]
Arriola, Armando Baigts [1 ]
Pesqueira, Gerardo Quinones [1 ]
Ruffini, Giulio [2 ]
Trenado, Carlos [3 ]
机构
[1] Natl Inst Neurol & Neurosurg Mexico, Dept Clin Neurophysiol, Mexico City, DF, Mexico
[2] Neuroelectrics Corp, Cambridge, MA USA
[3] Heinrich Heine Univ, Fac Med, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany
来源
关键词
tDCS; Lennox Gastaut syndrome; Seizure; Epilepsy; Transcranial direct current stimulation; Refractory seizure; TEMPORAL-LOBE EPILEPSY; MOTOR CORTEX EXCITABILITY; SEIZURE FREQUENCY; DC POLARIZATION; TRIAL; FEASIBILITY; MODULATION; MECHANISMS; PLASTICITY; SHIFTS;
D O I
10.1016/j.seizure.2022.06.009
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: Lennox-Gastaut Syndrome (SLG) is a severe form of childhood refractory epilepsy. Only one pilot study has been conducted using cathodal transcranial direct current stimulation (c-tDCs; 2mAx30minx5days) in LGS with promising results (-99% seizure reduction at 5 days). Our aim was to explore and replicate the efficacy and safety of 10 daily sessions of c-tDCs in SLG. Methods: We conducted a one-blinded, single-center pilot clinical study of c-tDCs (2mAx 30 min x 10 days), applied over the highest amplitude or frequent epileptiform interictal discharges areas using scalp EEG re-cordings without changes in their treatments. The tDCS device used was Enobio EEG (R) (Neuroelectrics, Barce-lona, Spain). The primary outcome was based on the seizure frequency using seizure diaries before, during 10 days of treatment, and then on a 4 and 8 weeks of follow-up. The rate of adverse events was recorded as a secondary outcome. Descriptive statistics and Wilcoxon signed-rank test were used Results: Twenty-four patients were enrolled. The mean age was 10.1 +/- 5.8 years old and 75% male. All the patients had severe mental retardation and abnormal neurological examinations. A significant median percentual seizure frequency reduction was found: 68.12% (p = 0.05) at 1 week, 68.12% (p = 0.002) in the second week. We found no significant reduction at 1 and 2 months; mainly tonic and atonic seizures were reduced significantly at all times. Only mild self-limited side effects were recorded mainly itching and erythema in the application zone Conclusion: Ten sessions of c-tDCs in combination with pharmacologic treatment in LGS is safe and appears to reduce significatively tonic and atonic seizure frequency at 2 months of follow-up.
引用
收藏
页码:44 / 50
页数:7
相关论文
共 50 条
  • [41] Transcranial direct current stimulation in treatment-resistant obsessive-compulsive disorder: An open-label pilot study
    Bation, Remy
    Poulet, Emmanuel
    Haesebaert, Frederic
    Saoud, Mohamed
    Brunelin, Jerome
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2016, 65 : 153 - 157
  • [42] Efficacy and safety of pantoprazole and itopride in patients with overlap of gastroesophageal reflux disease and dyspepsia: A prospective, open-label, single-arm pilot study
    Lakhtakia, Sundeep
    Singh, Aniruddha P.
    Singla, Neeraj
    Memon, Sana F.
    Reddy, Duvvur N.
    JGH OPEN, 2024, 8 (02):
  • [43] Effect of Erythropoietin-stimulating agent on uremic neuropathy in hemodialysis patients: a single-center open-label prospective study
    Amal T. Khafagi
    Mohamed A. Yehia
    Amal K. Helmy
    Waleed Hassan
    Nashwa Abdelhakim
    The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 58
  • [44] Effect of Erythropoietin-stimulating agent on uremic neuropathy in hemodialysis patients: a single-center open-label prospective study
    Khafagi, Amal T.
    Yehia, Mohamed A.
    Helmy, Amal K.
    Hassan, Waleed
    Abdelhakim, Nashwa
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2022, 58 (01):
  • [45] A SINGLE-CENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF REPEATED SUBCUTANEOUS INJECTIONS OF LANREOTIDE AUTOGEL IN PATIENTS WITH ACROMEGALY PREVIOUSLY TREATED WITH OCTREOTIDE
    Kelly, Phillip
    Maher, Kathy T.
    Chew, Shern L.
    Monson, John E.
    Grossman, Ashley B.
    Jenkins, Paul J.
    ENDOCRINE PRACTICE, 2010, 16 (02) : 191 - 197
  • [46] A Single-center, Open-label, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of the Indirect Bonding Technique
    Murakami, Takashi
    Kawanabe, Noriaki
    Kataoka, Tomoki
    Hoshijima, Mitsuhiro
    Komori, Hiroki
    Fujisawa, Atsuro
    Kamioka, Hiroshi
    ACTA MEDICA OKAYAMA, 2016, 70 (05) : 413 - 416
  • [47] Efficacy and safety of perampanel in a randomized, placebo-controlled trial with an open-label extension in patients with seizures associated with Lennox-Gastaut syndrome (LGS)
    Porter, Brenda
    Kira, Ryutaro
    Lee, Jeehun
    Aeby, Alec
    Patten, Anna
    Ngo, Leock
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [48] Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
    Yang, Dawei
    Ju, Minjie
    Wang, Hao
    Jia, Yichen
    Wang, Xiaodan
    Fang, Hao
    Fan, Jia
    BMC PHARMACOLOGY & TOXICOLOGY, 2023, 24 (01):
  • [49] Efficacy and safety of proxalutamide (GT0918) in severe or critically ill patients with COVID-19: study protocol for a prospective, open-label, single-arm, single-center exploratory trial
    Dawei Yang
    Minjie Ju
    Hao Wang
    Yichen Jia
    Xiaodan Wang
    Hao Fang
    Jia Fan
    BMC Pharmacology and Toxicology, 24
  • [50] Safety and efficacy of azilsartan in paediatric patients with hypertension: a phase 3, single-arm, open-label, prospective study
    Ito, Shuichi
    Nishiyama, Yuya
    Sugiura, Kenkichi
    Enya, Kazuaki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (04) : 350 - 358